COMPUGROUP MEDICAL SOCIETAS EUROPAEA

(COP)
  Report
Delayed Xetra  -  10/05 11:19:08 am EDT
69.35 EUR   +1.31%
05/06COMPUGROUP MEDICAL : Berenberg gives a Buy rating
MD
05/05CompuGroup Medical SE & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05COMPUGROUP MEDICAL : Baader Bank keeps its Buy rating
MD
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 3 0654 2243 7462 614--
Enterprise Value (EV)1 3 5054 7044 3743 1813 0772 997
P/E ratio 42,8x56,1x54,7x30,9x24,2x21,0x
Yield 0,78%0,64%0,70%1,13%1,27%1,42%
Capitalization / Revenue 4,11x5,04x3,65x2,38x2,25x2,14x
EV / Revenue 4,70x5,62x4,27x2,90x2,65x2,46x
EV / EBITDA 19,7x22,5x20,5x13,3x11,3x9,97x
Price to Book 11,9x6,62x6,08x3,91x3,54x3,24x
Nbr of stocks (in thousands) 48 07153 73552 64752 235--
Reference price (EUR) 63,878,671,250,150,150,1
Announcement Date 02/05/202002/04/202103/10/2022---
1 EUR in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 7468371 0251 0991 1601 219
EBITDA1 178209213238273300
Operating profit (EBIT)1 116134103137170194
Operating Margin 15,5%16,0%10,0%12,5%14,7%16,0%
Pre-Tax Profit (EBT)1 10911197,9123157180
Net income1 73,773,068,985,8110127
Net margin 9,88%8,71%6,72%7,81%9,48%10,4%
EPS2 1,491,401,301,622,072,38
Dividend per Share2 0,500,500,500,570,640,71
Announcement Date 02/05/202002/04/202103/10/2022---
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 Q3 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4
Net sales1 231243229241276279
EBITDA1 66,455,347,050,769,548,8
Operating profit (EBIT)1 -32,117,526,242,016,9
Operating Margin -13,2%7,66%10,9%15,2%6,05%
Pre-Tax Profit (EBT) ---24,9--
Net income1 ---17,228,412,4
Net margin ---7,13%10,3%4,44%
EPS2 -0,16-0,310,510,28
Dividend per Share ------
Announcement Date 11/05/202002/04/202105/06/202108/05/202111/04/202103/10/2022
1 EUR in Million
2 EUR
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 440480628567463382
Net Cash position1 ------
Leverage (Debt / EBITDA) 2,47x2,30x2,94x2,38x1,69x1,27x
Free Cash Flow1 95,894,910199,2125146
ROE (Net Profit / Equities) 28,3%21,9%16,5%14,4%16,0%17,0%
Shareholders' equity1 260333417597685745
ROA (Net Profit / Asset) 7,69%7,50%6,15%6,12%6,74%-
Assets1 9589731 1201 4021 630-
Book Value Per Share2 5,3511,911,712,814,115,4
Cash Flow per Share2 2,242,903,123,433,784,20
Capex1 43,755,164,271,570,472,6
Capex / Sales 5,86%6,58%6,26%6,50%6,07%5,96%
Announcement Date 02/05/202002/04/202103/10/2022---
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Key data
Capitalization (EUR) 2 614 361 750
Capitalization (USD) 2 743 584 584
Net sales (EUR) 1 025 300 000
Net sales (USD) 1 075 978 592
Number of employees 8 210
Sales / Employee (EUR) 124 884
Sales / Employee (USD) 131 057
Free-Float 48,8%
Free-Float capitalization (EUR) 1 276 204 470
Free-Float capitalization (USD) 1 339 284 783
Avg. Exchange 20 sessions (EUR) 5 358 813
Avg. Exchange 20 sessions (USD) 5 623 689
Average Daily Capital Traded 0,20%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA